Using dose–response characteristics of therapeutic agents for treatment decisions in type 2 diabetes
- 1 May 2000
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 2 (3) , 139-147
- https://doi.org/10.1046/j.1463-1326.2000.00054.x
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly Type 2 diabetic patientsDiabetic Medicine, 1998
- Troglitazone Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled StudyJournal of Clinical Endocrinology & Metabolism, 1998
- TroglitazoneDrugs, 1997
- Efficacy, Safety, and Dose-Response Characteristics of Glipizide Gastrointestinal Therapeutic System on Glycemic Control and Insulin Secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trialsDiabetes Care, 1997
- A Dose-Response Study of Glimepiride in Patients With NIDDM Who Have Previously Received Sulfonylurea AgentsDiabetes Care, 1996
- The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II DiabetesDiabetes Care, 1996
- Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled studyDiabetes Care, 1994
- Comparative Tolerability Profiles of Oral Antidiabetic AgentsDrug Safety, 1994
- Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groupsDiabetes Care, 1993
- Combined metformin-sulfonylurea treatment of patients with noninsulin- dependent diabetes in fair to poor glycemic controlJournal of Clinical Endocrinology & Metabolism, 1992